Minerva Neurosciences, Inc.

NasdaqCM:NERV Stock Report

Market Cap: US$15.2m

Minerva Neurosciences Balance Sheet Health

Financial Health criteria checks 2/6

Minerva Neurosciences has a total shareholder equity of $-21.7M and total debt of $60.0M, which brings its debt-to-equity ratio to -276.9%. Its total assets and total liabilities are $42.8M and $64.5M respectively.

Key information

-276.9%

Debt to equity ratio

US$60.00m

Debt

Interest coverage ration/a
CashUS$26.53m
Equity-US$21.67m
Total liabilitiesUS$64.48m
Total assetsUS$42.81m

Recent financial health updates

We're Hopeful That Minerva Neurosciences (NASDAQ:NERV) Will Use Its Cash Wisely

Jun 22
We're Hopeful That Minerva Neurosciences (NASDAQ:NERV) Will Use Its Cash Wisely

Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Deliver On Growth Plans?

Jan 26
Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Deliver On Growth Plans?

Recent updates

Minerva says FDA declined to accept marketing application for schizophrenia drug

Oct 17

Minerva Neurosciences: Biotech On The Move

Aug 29

Minerva stock rises on filing for FDA approval of schizophrenia therapy

Aug 22

We're Hopeful That Minerva Neurosciences (NASDAQ:NERV) Will Use Its Cash Wisely

Jun 22
We're Hopeful That Minerva Neurosciences (NASDAQ:NERV) Will Use Its Cash Wisely

Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Deliver On Growth Plans?

Jan 26
Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation

Oct 02
Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation

Minerva Neurosciences' (NASDAQ:NERV) Shareholders Are Down 59% On Their Shares

Mar 03
Minerva Neurosciences' (NASDAQ:NERV) Shareholders Are Down 59% On Their Shares

What You Need To Know About Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Investor Composition

Jan 27
What You Need To Know About Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Investor Composition

We're Keeping An Eye On Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Rate

Dec 23
We're Keeping An Eye On Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Rate

A Potential Trade Arises On Minerva

Dec 09

A Look At Minerva Neurosciences' (NASDAQ:NERV) Share Price Returns

Nov 18
A Look At Minerva Neurosciences' (NASDAQ:NERV) Share Price Returns

Minerva Neurosciences EPS beats by $0.03

Nov 02

Financial Position Analysis

Short Term Liabilities: NERV has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: NERV has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: NERV has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: NERV's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NERV has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: NERV has sufficient cash runway for 1 years if free cash flow continues to grow at historical rates of 16.8% each year.


Discover healthy companies